Browse studies

Find your next paid study

52 recruiting studies matching your filters

A Phase 1/2, Open-label, Multicenter Trial to Assess the Safety and Efficacy of ARD103 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

This is a phase I/2, interventional, open-label, multicenter study to assess the safety and efficacy of ARD103 in patients with relapsed or refractory acute my…

Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia RefractoryMDS (Myelodysplastic Syndrome)

Estimated

~$10 – $8,750

ARCE Therapeutics, Inc.NCT06680752

Phase 1

A Phase I Study Investigating the Safety & Efficacy of Danvatirsen as Monotherapy Followed by Combination With Venetoclax in Patients With Relapsed/Refractory MDS & AML

This is a Phase 1 study investigating the safety and efficacy of Danvatirsen as a monotherapy followed by combination with Venetoclax in patients with relapsed…

AML/MDSAcute Myeloid LeukemiaMyelodysplastic Syndromes

Estimated

~$10 – $6,250

Montefiore Medical CenterNCT05986240

A Long-term Follow-up Study to Assess Safety in Participants Who Received an Investigational T-Cell Receptor Engineered T-Cell (TCR-T) Product

The purpose of this Long-Term Follow-Up (LTFU) study is to monitor participants who have previously received TSC-100 or TSC-101 TCR-T therapies in the TSCAN-00…

AMLALLMDS

Estimated

~$10 – $1,050

TScan Therapeutics, Inc.NCT06976736

Phase 2

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who hav…

AML (Acute Myelogenous Leukemia)Acute Lymphoid Leukemia (ALL)Acute Leukemia (Category)+8 more

Estimated

~$10 – $7,500

Center for International Blood and Marrow Transplant ResearchNCT06859424

Phase 1

Phase 1/2 Study: CD45RA Depleted Peripheral Stem Cell Addback to Prevent Viral and Fungal Infections Following Alternative Donor TCRab/CD19 Depleted Hematopoietic Stem Cell Transplant

The major morbidities of allogeneic hematopoietic stem cell transplant (HSCT) using donors that are not human leukocyte antigen (HLA) matched siblings are graf…

LeukemiaHigh Risk Acute Lymphoblastic LeukemiaHigh Risk Acute Myeloid Leukemia+11 more

Estimated

~$10 – $6,250

Children's Hospital of PhiladelphiaNCT06839456

Phase 1

Phase 1 Study of Oral Tetrahydrouridine-Decitabine to Treat Relapsed or Refractory Myelodysplastic Syndromes

The goal of this clinical trial is to learn about the safety and effectiveness of the combination drug Tetrahydrouridine (THU) and decitabine (DEC) to treat pa…

MDS

Estimated

~$10 – $7,500

Treebough TherapiesNCT07006025

Phase 2

A Phase II Trial of HSCT for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine

The purpose of this study is to determine whether the use of lower doses of busulfan and the elimination of cyclosporine will further reduce transplant-related…

Fanconi AnemiaSevere Marrow FailureMyelodysplastic Syndrome (MDS)+1 more

Estimated

~$10 – $5,625

Children's Hospital Medical Center, CincinnatiNCT02143830

Phase 1

A Phase 1 Study of Allogenic Off-the-Shelf Multi-Tumor-Associated Antigen-Specific T Cell Products (MT-401-OTS) Administered to Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndromes (RAPID)

This study is a Phase 1 multicenter, open-label study evaluating the safety and efficacy of escalating doses of MT-401-OTS in 2 participant populations: 1) Tho…

Acute Myeloid Leukemia, in RelapseMDS

Estimated

~$10 – $8,750

Marker Therapeutics, Inc.NCT06552416

Development of a Peripheral Blood Assay to Replace BM Evaluation in Cytopenia - a Multi-Center Observational Study

This observational, multi-center study aims to collect data in order to develop a novel, minimally invasive diagnostic tool for MDS based on peripheral blood p…

CytopeniaMDS

Estimated

~$10 – $1,125

Weizmann Institute of ScienceNCT07081087

Phase 1

The ABNL-MARRO 001 Study: A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes.

ABNL-MARRO (A Basket study of Novel therapy for untreated MDS/MPN and Relapsed/Refractory Overlap Syndromes) is an international European-American cooperation …

MDS/MPN

Estimated

~$10 – $7,500

Michael SavonaNCT04061421

Phase 1

An Open-Label Phase 1b Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

This is an open-label Phase 1b study of NEROFE following a traditional 3+3 design to assess safety and to determine the Recommended Phase 2 Dose (RP2D) of NERO…

Advanced MDSAML

Estimated

~$10 – $8,750

Immune System Key LtdNCT04365179

Phase 1

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

The study participant has one of the following blood cancers: acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (B-…

Hematologic MalignancyALL, ChildhoodAML, Childhood+2 more

Estimated

~$10 – $6,250

St. Jude Children's Research HospitalNCT06326463